NKTR
Nektar Therapeutics$68.42+1.25 (+1.87%)Prev Close$67.17·MCap$1.31B·P/E—·Vol420.7K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
19
$3.33M
◆
Net Activity
Net Seller
$3.33M
●
Active Insiders
3
last 12 mo
Over the past 12 months, insider activity at Nektar Therapeutics (NKTR) has been exclusively selling, with 0 insider purchases totaling $0.00 and 19 insider sales totaling $3.33M. The most recent insider transaction was by Zalevsky Jonathan (officer: Chief R&D Officer), who sold $397.7K worth of shares on Jul 2, 2026. Nektar Therapeutics operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.31B.
NKTR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 5,681 | $70.00 | $397.7K | 9,756-37% |
| Jun 18, 2026 | ROBIN HOWARD W | director, officer: President & CEO | Sell | 20,000 | $60.75 | $1.22M | 69,742 |
| Jun 17, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 5,538 | $60.71 | $336.2K | 15,437-26% |
| May 21, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 199 | $65.51 | $13.0K | 20,975 |
| May 21, 2026 | ROBIN HOWARD W | director, officer: President & CEO | Sell | 444 | $65.51 | $29.1K | 75,045 |
| Feb 18, 2026 | ROBIN HOWARD W | President & CEO | Sell | 423 | $73.00 | $30.9K | 0 |
| Feb 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 0 |
| Jan 22, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 3,867 | $35.67 | $137.9K | 21,354 |
| Nov 25, 2025 | ROBIN HOWARD W | President & CEO | Sell | 2,207 | $54.28 | $119.8K | 54,245 |
| Nov 25, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 630 | $54.28 | $34.2K | 21,585 |
| Nov 25, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,157 | $54.28 | $62.8K | 18,971 |
| Sep 11, 2025 | ROBIN HOWARD W | President & CEO | Sell | 6,666 | $46.69 | $311.2K | 53,908 |
| Sep 8, 2025 | ROBIN HOWARD W | President & CEO | Sell | 11,832 | $36.42 | $431.0K | 65,917 |
| Sep 8, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,721 | $33.52 | $57.7K | 18,390 |
| Sep 4, 2025 | ROBIN HOWARD W | President & CEO | Sell | 1,500 | $30.16 | $45.2K | 67,840 |
| Sep 4, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 485 | $30.10 | $14.6K | 19,183 |
| Aug 21, 2025 | ROBIN HOWARD W | President & CEO | Sell | 1,573 | $26.59 | $41.8K | 69,340 |
| Aug 21, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 676 | $26.59 | $18.0K | 20,312 |
| Aug 21, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 725 | $26.59 | $19.3K | 19,668 |
| May 21, 2025 | ROBIN HOWARD W | President & CEO | Sell | 23,208 | $0.67 | $15.5K | 1,063,693 |
| May 21, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 9,996 | $0.67 | $6.7K | 314,296 |
| May 21, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,712 | $0.67 | $7.2K | 305,892 |
| Feb 21, 2025 | ROBIN HOWARD W | President & CEO | Sell | 23,774 | $1.01 | $24.0K | 1,086,901 |
| Feb 21, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 11,040 | $1.01 | $11.2K | 324,292 |
| Feb 21, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,300 | $1.01 | $10.4K | 316,604 |
| Dec 26, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 49,962 | $0.90 | $44.8K | 351,892 |
| Dec 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 51,115 | $0.94 | $48.0K | 326,904 |
| Dec 19, 2024 | ROBIN HOWARD W | President & CEO | Sell | 132,030 | $1.00 | $131.7K0.7% OS | 1,195,710 |
| Nov 20, 2024 | ROBIN HOWARD W | President & CEO | Sell | 16,278 | $1.01 | $16.4K | 832,080 |
| Nov 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,407 | $1.01 | $6.5K | 218,856 |
| Nov 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,785 | $1.01 | $7.9K | 243,019 |
| Aug 20, 2024 | ROBIN HOWARD W | President & CEO | Sell | 14,881 | $1.28 | $19.0K | 848,358 |
| Aug 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 5,651 | $1.28 | $7.2K | 225,263 |
| Aug 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 6,866 | $1.28 | $8.8K | 250,804 |
| Jun 14, 2024 | CHESS ROBERT | Sell | 19,500 | $1.20 | $23.4K | 255,273 | |
| May 20, 2024 | ROBIN HOWARD W | President & CEO | Sell | 16,650 | $1.75 | $29.1K | 863,239 |
| May 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,260 | $1.75 | $11.0K | 230,414 |
| May 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,355 | $1.75 | $12.9K | 257,670 |
| May 13, 2024 | Deep Track Capital, LP | Sell | 56,000 | $1.78 | $99.6K | 18,344,000 | |
| Feb 22, 2024 | ROBIN HOWARD W | President & CEO | Sell | 20,033 | $0.68 | $13.6K | 879,889 |
| Feb 22, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,606 | $0.68 | $5.2K | 236,674 |
| Feb 22, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,014 | $0.68 | $6.1K | 265,025 |
| Nov 20, 2023 | ROBIN HOWARD W | President & CEO | Sell | 19,877 | $0.49 | $9.7K | 899,922 |
| Nov 20, 2023 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,179 | $0.49 | $3.5K | 243,780 |
| Nov 20, 2023 | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,646 | $0.49 | $4.7K | 274,039 |
| Sep 20, 2023 | Ajer Jeffrey Robert | Director | Sell | 4,359 | $0.69 | $3.0K | 34,153 |
| Sep 20, 2023 | CHESS ROBERT | Director | Sell | 10,200 | $0.67 | $6.8K | 274,773 |
| Sep 20, 2023 | Curet Myriam | Director | Sell | 4,359 | $0.69 | $3.0K | 27,418 |
| Aug 17, 2023 | ROBIN HOWARD W | President & CEO | Sell | 19,998 | $0.78 | $15.6K | 919,799 |
| Aug 17, 2023 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,221 | $0.78 | $5.6K | 250,959 |
Showing 1–50 of 109
1 / 3
NKTR Insider Buying Activity
The following table shows recent insider purchases of Nektar Therapeutics (NKTR) stock reported via SEC Form 4 filings.
No insider buying activity found for NKTR in the last 12 months.
NKTR Insider Selling Activity
The following table shows recent insider sales of Nektar Therapeutics (NKTR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 5,681 | $70.00 | $397.7K | 9,756-37% |
| Jun 18, 2026 | ROBIN HOWARD W | director, officer: President & CEO | Sell | 20,000 | $60.75 | $1.22M | 69,742 |
| Jun 17, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 5,538 | $60.71 | $336.2K | 15,437-26% |
| May 21, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 199 | $65.51 | $13.0K | 20,975 |
| May 21, 2026 | ROBIN HOWARD W | director, officer: President & CEO | Sell | 444 | $65.51 | $29.1K | 75,045 |
| Feb 18, 2026 | ROBIN HOWARD W | President & CEO | Sell | 423 | $73.00 | $30.9K | 0 |
| Feb 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 0 |
| Jan 22, 2026 | Zalevsky Jonathan | officer: Chief R&D Officer | Sell | 3,867 | $35.67 | $137.9K | 21,354 |
| Nov 25, 2025 | ROBIN HOWARD W | President & CEO | Sell | 2,207 | $54.28 | $119.8K | 54,245 |
| Nov 25, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 630 | $54.28 | $34.2K | 21,585 |
| Nov 25, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,157 | $54.28 | $62.8K | 18,971 |
| Sep 11, 2025 | ROBIN HOWARD W | President & CEO | Sell | 6,666 | $46.69 | $311.2K | 53,908 |
| Sep 8, 2025 | ROBIN HOWARD W | President & CEO | Sell | 11,832 | $36.42 | $431.0K | 65,917 |
| Sep 8, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 1,721 | $33.52 | $57.7K | 18,390 |
| Sep 4, 2025 | ROBIN HOWARD W | President & CEO | Sell | 1,500 | $30.16 | $45.2K | 67,840 |
| Sep 4, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 485 | $30.10 | $14.6K | 19,183 |
| Aug 21, 2025 | ROBIN HOWARD W | President & CEO | Sell | 1,573 | $26.59 | $41.8K | 69,340 |
| Aug 21, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 676 | $26.59 | $18.0K | 20,312 |
| Aug 21, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 725 | $26.59 | $19.3K | 19,668 |
| May 21, 2025 | ROBIN HOWARD W | President & CEO | Sell | 23,208 | $0.67 | $15.5K | 1,063,693 |
| May 21, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 9,996 | $0.67 | $6.7K | 314,296 |
| May 21, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,712 | $0.67 | $7.2K | 305,892 |
| Feb 21, 2025 | ROBIN HOWARD W | President & CEO | Sell | 23,774 | $1.01 | $24.0K | 1,086,901 |
| Feb 21, 2025 | Wilson Mark Andrew | Chief Legal Officer | Sell | 11,040 | $1.01 | $11.2K | 324,292 |
| Feb 21, 2025 | Zalevsky Jonathan | Chief R&D Officer | Sell | 10,300 | $1.01 | $10.4K | 316,604 |
| Dec 26, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 49,962 | $0.90 | $44.8K | 351,892 |
| Dec 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 51,115 | $0.94 | $48.0K | 326,904 |
| Dec 19, 2024 | ROBIN HOWARD W | President & CEO | Sell | 132,030 | $1.00 | $131.7K0.7% OS | 1,195,710 |
| Nov 20, 2024 | ROBIN HOWARD W | President & CEO | Sell | 16,278 | $1.01 | $16.4K | 832,080 |
| Nov 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,407 | $1.01 | $6.5K | 218,856 |
| Nov 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,785 | $1.01 | $7.9K | 243,019 |
| Aug 20, 2024 | ROBIN HOWARD W | President & CEO | Sell | 14,881 | $1.28 | $19.0K | 848,358 |
| Aug 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 5,651 | $1.28 | $7.2K | 225,263 |
| Aug 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 6,866 | $1.28 | $8.8K | 250,804 |
| Jun 14, 2024 | CHESS ROBERT | Sell | 19,500 | $1.20 | $23.4K | 255,273 | |
| May 20, 2024 | ROBIN HOWARD W | President & CEO | Sell | 16,650 | $1.75 | $29.1K | 863,239 |
| May 20, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 6,260 | $1.75 | $11.0K | 230,414 |
| May 20, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 7,355 | $1.75 | $12.9K | 257,670 |
| May 13, 2024 | Deep Track Capital, LP | Sell | 56,000 | $1.78 | $99.6K | 18,344,000 | |
| Feb 22, 2024 | ROBIN HOWARD W | President & CEO | Sell | 20,033 | $0.68 | $13.6K | 879,889 |
| Feb 22, 2024 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,606 | $0.68 | $5.2K | 236,674 |
| Feb 22, 2024 | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,014 | $0.68 | $6.1K | 265,025 |
| Nov 20, 2023 | ROBIN HOWARD W | President & CEO | Sell | 19,877 | $0.49 | $9.7K | 899,922 |
| Nov 20, 2023 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,179 | $0.49 | $3.5K | 243,780 |
| Nov 20, 2023 | Zalevsky Jonathan | Chief R&D Officer | Sell | 9,646 | $0.49 | $4.7K | 274,039 |
| Sep 20, 2023 | Ajer Jeffrey Robert | Director | Sell | 4,359 | $0.69 | $3.0K | 34,153 |
| Sep 20, 2023 | CHESS ROBERT | Director | Sell | 10,200 | $0.67 | $6.8K | 274,773 |
| Sep 20, 2023 | Curet Myriam | Director | Sell | 4,359 | $0.69 | $3.0K | 27,418 |
| Aug 17, 2023 | ROBIN HOWARD W | President & CEO | Sell | 19,998 | $0.78 | $15.6K | 919,799 |
| Aug 17, 2023 | Wilson Mark Andrew | Chief Legal Officer | Sell | 7,221 | $0.78 | $5.6K | 250,959 |
NKTR Insiders
Similar Stocks to NKTR
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B